Tim W. H. Rijnhout
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tim W. H. Rijnhout has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Femke Noorman
Military Blood Bank Ministry of Defense Utrecht The Netherlands
6 shared publications Rigo Hoencamp
Department of Surgery Alrijne Medical Centre Leiderdorp The Netherlands
6 shared publications- Edward Camillus Thwan Han Tan
Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands
4 shared publications Femke Noorman
Military Blood Bank
4 shared publicationsMargreet Zoodsma
Military Blood Bank, Ministry of Defense, 3584 EZ Utrecht, The Netherlands
4 shared publications- Michael H. J. Verhofstad
Trauma Research Unit Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
4 shared publications
Latest Publications
- 18 May 2026
- Published byĀ WileyĀ inĀ Transfusion
- Vol.Ā 66 Ā (8) , 1536-1551
Barriers and facilitators to cell saver use in damage control surgery
Background: Cell savers reduce the use of allogeneic blood and can serve as an important adjunct during blood shortages. This study investigates the user perspective on cell saver (CS) use during damage control surgery (DCS) in the Netherlands. Study Design and Methods: A survey was conducted amongst trauma surgeons and anesthesiologists from Dutch level 1 trauma centers and militaryāaffiliated hospitals. The survey assessed the perceived usability and usefulness of CS in DCS, addressing factors such as logistics, training, experience, (contra)indications, and perceived suitability of CS or reinfusion of unwashed salvaged blood during blood shortages. Responses were analyzed using a fiveāpoint scale. Results: 195 of the 707 (28%) invited clinicians completed the survey. Most rated CS as very useful or essential during DCS (trauma surgeons: 58%, anesthesiologists: 64%). Staff (90%) and disposables (84%) were reportedly available, but reported concerns included CS being timeāconsuming (trauma: 23%, anesthesia: 40%), contamination risk from gastrointestinal injuries (trauma: 37%, anesthesia: 21%), and insufficient suction power (trauma: 19%, anesthesia: 10%). During blood shortages, most respondents considered CS suitable for DCS (trauma: 54%, anesthesia: 63%), but fewer supported reinfusion of unwashed salvaged blood (trauma: 62%, anesthesia: 25%). Discussion: The routine use of CS during DCS may be hampered by practical and clinical barriers, such as time constraints, limited training, and the risk of complications. Targeting these areas and correlating these findings to clinical outcomes may increase the use of autologous blood transfusion techniques.
- 18 May 2026
- Published byĀ WileyĀ inĀ Transfusion
- Vol.Ā 66 Ā (8) , 1536-1551
Barriers and facilitators to cell saver use in damage control surgery
Background: Cell savers reduce the use of allogeneic blood and can serve as an important adjunct during blood shortages. This study investigates the user perspective on cell saver (CS) use during damage control surgery (DCS) in the Netherlands. Study Design and Methods: A survey was conducted amongst trauma surgeons and anesthesiologists from Dutch level 1 trauma centers and militaryāaffiliated hospitals. The survey assessed the perceived usability and usefulness of CS in DCS, addressing factors such as logistics, training, experience, (contra)indications, and perceived suitability of CS or reinfusion of unwashed salvaged blood during blood shortages. Responses were analyzed using a fiveāpoint scale. Results: 195 of the 707 (28%) invited clinicians completed the survey. Most rated CS as very useful or essential during DCS (trauma surgeons: 58%, anesthesiologists: 64%). Staff (90%) and disposables (84%) were reportedly available, but reported concerns included CS being timeāconsuming (trauma: 23%, anesthesia: 40%), contamination risk from gastrointestinal injuries (trauma: 37%, anesthesia: 21%), and insufficient suction power (trauma: 19%, anesthesia: 10%). During blood shortages, most respondents considered CS suitable for DCS (trauma: 54%, anesthesia: 63%), but fewer supported reinfusion of unwashed salvaged blood (trauma: 62%, anesthesia: 25%). Discussion: The routine use of CS during DCS may be hampered by practical and clinical barriers, such as time constraints, limited training, and the risk of complications. Targeting these areas and correlating these findings to clinical outcomes may increase the use of autologous blood transfusion techniques.
- Open Access
- 15 October 2024
- Published byĀ Springer NatureĀ inĀ BMC Emergency Medicine
- Vol.Ā 24 Ā (1) , 1-6
Effectiveness of intraosseous access during resuscitation: a retrospective cohort study
Purpose: During resuscitation in emergency situations, establishing intravascular access is crucial for promptly initiating delivery of fluids, blood, blood products, and medications. In cases of emergency, when intravenous (IV) access proves unsuccessful, intraosseous (IO) access serves as a viable alternative. However, there is a notable lack of information concerning the frequency and efficacy of IO access in acute care settings. This study aims to assess the efficacy of intraosseous (IO) access in acute care settings, especially focusing on children in a level 1 trauma center. Methods: This retrospective study included patients with IO access presented in a level 1 trauma center emergency department (ED) between January 2015 and April 2020. Data regarding medication and fluid infusion was documented, and the clinical success rate was calculated. Results: Of the 109,548 patients that were admitted to the ED, 25,686 IV lines were inserted. Documentation of 188 patients of which 73 (38.8%) children was complete and used for analysis. In these 188 patients, a total of 232 IO accesses were placed. Overall, 182 patients had a functional IO access (204 needles) (88%). In children (age < 18 years) success rate was lower as compared to adults, 71ā84% as compared to 94%. However, univariate regression showed no association between the percentage of functional IO access and gender, age, weight, health care location (prehospital and in hospital), anatomical position (tibia as compared to humerus) or type of injury. Conclusion: Intraosseous access demonstrates a high success rate for infusion, independent of gender, age, weight, anatomical positioning, or healthcare setting, with minimal complication rates. Caution is especially warranted for children under the age of six months, since success rate was lower.
- 15 October 2024
- Published byĀ Springer NatureĀ inĀ BMC Emergency Medicine
- Vol.Ā 24 Ā (1) , 1-6
Open AccessEffectiveness of intraosseous access during resuscitation: a retrospective cohort study
Purpose: During resuscitation in emergency situations, establishing intravascular access is crucial for promptly initiating delivery of fluids, blood, blood products, and medications. In cases of emergency, when intravenous (IV) access proves unsuccessful, intraosseous (IO) access serves as a viable alternative. However, there is a notable lack of information concerning the frequency and efficacy of IO access in acute care settings. This study aims to assess the efficacy of intraosseous (IO) access in acute care settings, especially focusing on children in a level 1 trauma center. Methods: This retrospective study included patients with IO access presented in a level 1 trauma center emergency department (ED) between January 2015 and April 2020. Data regarding medication and fluid infusion was documented, and the clinical success rate was calculated. Results: Of the 109,548 patients that were admitted to the ED, 25,686 IV lines were inserted. Documentation of 188 patients of which 73 (38.8%) children was complete and used for analysis. In these 188 patients, a total of 232 IO accesses were placed. Overall, 182 patients had a functional IO access (204 needles) (88%). In children (age < 18 years) success rate was lower as compared to adults, 71ā84% as compared to 94%. However, univariate regression showed no association between the percentage of functional IO access and gender, age, weight, health care location (prehospital and in hospital), anatomical position (tibia as compared to humerus) or type of injury. Conclusion: Intraosseous access demonstrates a high success rate for infusion, independent of gender, age, weight, anatomical positioning, or healthcare setting, with minimal complication rates. Caution is especially warranted for children under the age of six months, since success rate was lower.
- Open Access
- 1 November 2022
- Published byĀ WileyĀ inĀ Transfusion
- Vol.Ā 63 Ā (1) , 203-216
Frozen for combat: Quality of deepāfrozen thrombocytes, produced and used by The Netherlands Armed Forces 2001ā2021
Background: The Netherlands Armed Forces (NLAF) are using ā80°C deepāfrozen thrombocyte concentrate (DTC) since 2001. The aim of this study is to investigate the effect of storage duration and alterations in production/measurement techniques on DTC quality. It is expected that DTC quality is unaffected by storage duration and in compliance with the European guidelines for fresh and cryopreserved platelets.Study Design and Methods: Preāfreeze and postāthaw product platelet content and recovery were collected to analyze the effects of dimethyl sulfoxide (DMSO) type, duration of frozen storage (DMSOā1 max 12 years and DMSOā2 frozen DTC max 4 years at ā80°C) and type of plasma used to suspend DTC. Coagulation characteristics of thawed DTC, plasma and supernatant of DTC (2Ć 2500 G) were measured with Kaolin thromboelastography (TEG) and phospholipid (PPL) activity assay.Results: Platelet content and recovery of DTC is ±10%ā15% lower in shortāstored products and remained stable when stored beyond 0.5 years. Thawed DTC (n = 1724) were compliant to the European guidelines (98.1% postāthaw product recovery ā„50% from original product, 98.3% ā„200 Ć 109 platelets/unit). Compared to DMSOā1, products frozen with DMSOā2 showed ±8% reduced thawāfreeze recovery, a higher TEG clot strength (MA 58 [6] vs. 64 [8] mm) and same ±11 s PPL clotting time. The use of coldāstored thawed plasma instead of fresh thawed plasma did not influence product recovery or TEGāMA.Discussion: Regardless of alterations, product quality was in compliance with European guidelines and unaffected by storage duration up to 12 years of ā80°C frozen storage.
- 1 November 2022
- Published byĀ WileyĀ inĀ Transfusion
- Vol.Ā 63 Ā (1) , 203-216
Open AccessFrozen for combat: Quality of deepāfrozen thrombocytes, produced and used by The Netherlands Armed Forces 2001ā2021
Background: The Netherlands Armed Forces (NLAF) are using ā80°C deepāfrozen thrombocyte concentrate (DTC) since 2001. The aim of this study is to investigate the effect of storage duration and alterations in production/measurement techniques on DTC quality. It is expected that DTC quality is unaffected by storage duration and in compliance with the European guidelines for fresh and cryopreserved platelets.Study Design and Methods: Preāfreeze and postāthaw product platelet content and recovery were collected to analyze the effects of dimethyl sulfoxide (DMSO) type, duration of frozen storage (DMSOā1 max 12 years and DMSOā2 frozen DTC max 4 years at ā80°C) and type of plasma used to suspend DTC. Coagulation characteristics of thawed DTC, plasma and supernatant of DTC (2Ć 2500 G) were measured with Kaolin thromboelastography (TEG) and phospholipid (PPL) activity assay.Results: Platelet content and recovery of DTC is ±10%ā15% lower in shortāstored products and remained stable when stored beyond 0.5 years. Thawed DTC (n = 1724) were compliant to the European guidelines (98.1% postāthaw product recovery ā„50% from original product, 98.3% ā„200 Ć 109 platelets/unit). Compared to DMSOā1, products frozen with DMSOā2 showed ±8% reduced thawāfreeze recovery, a higher TEG clot strength (MA 58 [6] vs. 64 [8] mm) and same ±11 s PPL clotting time. The use of coldāstored thawed plasma instead of fresh thawed plasma did not influence product recovery or TEGāMA.Discussion: Regardless of alterations, product quality was in compliance with European guidelines and unaffected by storage duration up to 12 years of ā80°C frozen storage.
- Open Access
- 24 September 2022
- Published byĀ Springer NatureĀ inĀ Trials
- Vol.Ā 23 Ā (1) , 1-9
The haemostatic effect of deep-frozen platelets versus room temperature-stored platelets in the treatment of surgical bleeding: MAFODāstudy protocol for a randomized controlled non-inferiority trial
Background: The Netherlands Armed Forces have been successfully using deep-frozen (ā 80 °C) thrombocyte concentrate (DTC) for the treatment of (massive) bleeding trauma patients in austere environments since 2001. However, high-quality evidence for the effectiveness and safety of DTCs is currently lacking. Therefore, the MAssive transfusion of Frozen bloOD (MAFOD) trial is designed to compare the haemostatic effect of DTCs versus room temperature-stored platelets (RSP) in the treatment of surgical bleeding.Methods: The MAFOD trial is a single-blinded, randomized controlled non-inferiority trial and will be conducted in three level 1 trauma centres in The Netherlands. Patients 12 years or older, alive at hospital presentation, requiring a massive transfusion including platelets and with signed (deferred) consent will be included. The primary outcome is the percentage of patients that have achieved haemostasis within 6 h and show signs of life. Haemostasis is defined as the time in minutes from arrival to the time of the last blood component transfusion (plasma/platelets or red blood cells), followed by a 2-h transfusion-free period. This is the first randomized controlled study investigating DTCs in trauma and vascular surgical bleeding.Discussion: The hypothesis is that the percentage of patients that will achieve haemostasis in the DTC group is at least equal to the RSP group (85%). With a power of 80%, a significance level of 5% and a non-inferiority limit of 15%, a total of 71 patients in each arm are required, thus resulting in a total of 158 patients, including a 10% refusal rate. The data collected during the study could help improve the use of platelets during resuscitation management. If proven non-inferior in civilian settings, frozen platelets may be used in the future to optimize logistics and improve platelet availability in rural or remote areas for the treatment of (massive) bleeding trauma patients in civilian settings.Trial registration: ClinicalTrials.gov NCT05502809. Registered on 16 August 2022.
- 24 September 2022
- Published byĀ Springer NatureĀ inĀ Trials
- Vol.Ā 23 Ā (1) , 1-9
Open AccessThe haemostatic effect of deep-frozen platelets versus room temperature-stored platelets in the treatment of surgical bleeding: MAFODāstudy protocol for a randomized controlled non-inferiority trial
Background: The Netherlands Armed Forces have been successfully using deep-frozen (ā 80 °C) thrombocyte concentrate (DTC) for the treatment of (massive) bleeding trauma patients in austere environments since 2001. However, high-quality evidence for the effectiveness and safety of DTCs is currently lacking. Therefore, the MAssive transfusion of Frozen bloOD (MAFOD) trial is designed to compare the haemostatic effect of DTCs versus room temperature-stored platelets (RSP) in the treatment of surgical bleeding.Methods: The MAFOD trial is a single-blinded, randomized controlled non-inferiority trial and will be conducted in three level 1 trauma centres in The Netherlands. Patients 12 years or older, alive at hospital presentation, requiring a massive transfusion including platelets and with signed (deferred) consent will be included. The primary outcome is the percentage of patients that have achieved haemostasis within 6 h and show signs of life. Haemostasis is defined as the time in minutes from arrival to the time of the last blood component transfusion (plasma/platelets or red blood cells), followed by a 2-h transfusion-free period. This is the first randomized controlled study investigating DTCs in trauma and vascular surgical bleeding.Discussion: The hypothesis is that the percentage of patients that will achieve haemostasis in the DTC group is at least equal to the RSP group (85%). With a power of 80%, a significance level of 5% and a non-inferiority limit of 15%, a total of 71 patients in each arm are required, thus resulting in a total of 158 patients, including a 10% refusal rate. The data collected during the study could help improve the use of platelets during resuscitation management. If proven non-inferior in civilian settings, frozen platelets may be used in the future to optimize logistics and improve platelet availability in rural or remote areas for the treatment of (massive) bleeding trauma patients in civilian settings.Trial registration: ClinicalTrials.gov NCT05502809. Registered on 16 August 2022.
- Open Access
- 12 September 2022
- Published byĀ Springer NatureĀ inĀ Research Square
The haemostatic effect of deep-frozen platelets versus room temperature stored platelets in the treatment of surgical bleeding. MAFOD: study protocol for a randomized controlled non-inferiority trial
Background : The Netherlands Armed Forces have been successfully using deep frozen (-80°C) thrombocyte concentrate (DTC) for the treatment of (massive) bleeding trauma patients in austere environments since 2001. However, high-quality evidence for effectiveness and safety of DTCs is currently lacking. Therefore, the MAssive transfusion of Frozen bloOD (MAFOD) trial is designed to compare the haemostatic effect of DTCs versus room temperature stored platelets (RSP) in the treatment of surgical bleeding. Methods : The MAFOD trial is a single-blinded, randomized controlled non-inferiority trial and will be conducted in three level 1 trauma centres in the Netherlands. Patients of 12 years or older, alive at hospital presentation, requiring a massive transfusion including platelets, and with signed (deferred) consent will be included. The primary outcome is the percentage of patients that have achieved haemostasis within six hours and show signs of life. Haemostasis is defined as the time in minutes from arrival to the time of the last blood component transfusion (plasma/platelets or red blood cells), followed by a two-hour transfusion free period. This is the first randomized controlled study investigating DTCs in trauma- and vascular surgical bleeding. Discussion: The hypothesis is that the percentage of patients that will achieve haemostasis in the DTC group is at least equal to the RSP group (85%). With a power of 80%, a significance level of 5% and a non-inferiority limit of 15%, a total of 71 patients in each arm are required. Thus, resulting in a total of 158 patients, including a 10% refusal rate. The data collected during the study could help improve the use of platelets during resuscitation management. If proven non-inferior in civilian setting, frozen platelets may be used in the future to optimize logistics and improve platelet availability in rural or remote areas for the treatment of (massive) bleeding trauma patients in civilian settings. Trial registration: ClinicalTrials.gov NCT05502809. Registered on 16 August 2022. Keywords : Transfusion; cryopreservation; trauma; bleeding; haemorrhage; platelets; resuscitation; injury; blood; coagulopathy
- 12 September 2022
- Published byĀ Springer NatureĀ inĀ Research Square
Open AccessThe haemostatic effect of deep-frozen platelets versus room temperature stored platelets in the treatment of surgical bleeding. MAFOD: study protocol for a randomized controlled non-inferiority trial
Background : The Netherlands Armed Forces have been successfully using deep frozen (-80°C) thrombocyte concentrate (DTC) for the treatment of (massive) bleeding trauma patients in austere environments since 2001. However, high-quality evidence for effectiveness and safety of DTCs is currently lacking. Therefore, the MAssive transfusion of Frozen bloOD (MAFOD) trial is designed to compare the haemostatic effect of DTCs versus room temperature stored platelets (RSP) in the treatment of surgical bleeding. Methods : The MAFOD trial is a single-blinded, randomized controlled non-inferiority trial and will be conducted in three level 1 trauma centres in the Netherlands. Patients of 12 years or older, alive at hospital presentation, requiring a massive transfusion including platelets, and with signed (deferred) consent will be included. The primary outcome is the percentage of patients that have achieved haemostasis within six hours and show signs of life. Haemostasis is defined as the time in minutes from arrival to the time of the last blood component transfusion (plasma/platelets or red blood cells), followed by a two-hour transfusion free period. This is the first randomized controlled study investigating DTCs in trauma- and vascular surgical bleeding. Discussion: The hypothesis is that the percentage of patients that will achieve haemostasis in the DTC group is at least equal to the RSP group (85%). With a power of 80%, a significance level of 5% and a non-inferiority limit of 15%, a total of 71 patients in each arm are required. Thus, resulting in a total of 158 patients, including a 10% refusal rate. The data collected during the study could help improve the use of platelets during resuscitation management. If proven non-inferior in civilian setting, frozen platelets may be used in the future to optimize logistics and improve platelet availability in rural or remote areas for the treatment of (massive) bleeding trauma patients in civilian settings. Trial registration: ClinicalTrials.gov NCT05502809. Registered on 16 August 2022. Keywords : Transfusion; cryopreservation; trauma; bleeding; haemorrhage; platelets; resuscitation; injury; blood; coagulopathy
- 2 July 2021
- Published byĀ Wolters Kluwer HealthĀ inĀ Journal of Trauma and Acute Care Surgery
- Vol.Ā 91 Ā (4) , 759-771
Platelet to erythrocyte transfusion ratio and mortality in massively transfused trauma patients. A systematic review and meta-analysis
BACKGROUND: Platelet transfusion during major hemorrhage is important and often embedded in massive transfusion protocols. However, the optimal ratio of platelets to erythrocytes (platelet-rich plasma [PLT]/red blood cell [RBC] ratio) remains unclear. We hypothesized that high PLT/RBC ratios, as compared with low PLT/RBC ratios, are associated with improved survival in patients requiring massive transfusion. METHODS: Four databases (Pubmed, CINAHL, EMBASE, and Cochrane) were systematically screened for literatures published until January 21, 2021, to determine the effect of PLT/RBC ratio on the primary outcome measure mortality at 1 hour to 6 hours and 24 hours and at 28 days to 30 days. Studies comparing various PLT/RBC ratios were included in the meta-analysis. Secondary outcomes included intensive care unit length of stay and in-hospital length of stay and total blood component use. The study protocol was registered in PROSPERO under number CRD42020165648. RESULTS: The search identified a total of 8903 records. After removing the duplicates and second screening of title, abstract, and full text, a total of 59 articles were included in the analysis. Of these articles, 12 were included in the meta-analysis. Mortality at 1 hour to 6 hours, 24 hours, and 28 days to 30 days was significantly lower for high PLT/RBC ratios as compared with low PLT/RBC ratios. CONCLUSION: Higher PLT/RBC ratios are associated with significantly lower 1-hour to 6-hour, 24-hour, 28-day to 30-day mortalities as compared with lower PLT/RBC ratios. The optimal PLT/RBC ratio for massive transfusion in trauma patients is approximately 1:1. LEVEL OF EVIDENCE: Systematic review and meta-analysis, therapeutic Level III.
- 2 July 2021
- Published byĀ Wolters Kluwer HealthĀ inĀ Journal of Trauma and Acute Care Surgery
- Vol.Ā 91 Ā (4) , 759-771
Platelet to erythrocyte transfusion ratio and mortality in massively transfused trauma patients. A systematic review and meta-analysis
BACKGROUND: Platelet transfusion during major hemorrhage is important and often embedded in massive transfusion protocols. However, the optimal ratio of platelets to erythrocytes (platelet-rich plasma [PLT]/red blood cell [RBC] ratio) remains unclear. We hypothesized that high PLT/RBC ratios, as compared with low PLT/RBC ratios, are associated with improved survival in patients requiring massive transfusion. METHODS: Four databases (Pubmed, CINAHL, EMBASE, and Cochrane) were systematically screened for literatures published until January 21, 2021, to determine the effect of PLT/RBC ratio on the primary outcome measure mortality at 1 hour to 6 hours and 24 hours and at 28 days to 30 days. Studies comparing various PLT/RBC ratios were included in the meta-analysis. Secondary outcomes included intensive care unit length of stay and in-hospital length of stay and total blood component use. The study protocol was registered in PROSPERO under number CRD42020165648. RESULTS: The search identified a total of 8903 records. After removing the duplicates and second screening of title, abstract, and full text, a total of 59 articles were included in the analysis. Of these articles, 12 were included in the meta-analysis. Mortality at 1 hour to 6 hours, 24 hours, and 28 days to 30 days was significantly lower for high PLT/RBC ratios as compared with low PLT/RBC ratios. CONCLUSION: Higher PLT/RBC ratios are associated with significantly lower 1-hour to 6-hour, 24-hour, 28-day to 30-day mortalities as compared with lower PLT/RBC ratios. The optimal PLT/RBC ratio for massive transfusion in trauma patients is approximately 1:1. LEVEL OF EVIDENCE: Systematic review and meta-analysis, therapeutic Level III.
- Open Access
- 21 July 2020
- Published byĀ WileyĀ inĀ Transfusion
- Vol.Ā 60 Ā (8) , 1846-1855
Prolonged (postāthaw) shelf life of ā80°C frozen AB apheresis plasma
BACKGROUND Early plasma transfusion is important in the treatment of patients with major hemorrhage. Prolonged shelf life of AB type frozen ā80°C and coldāstored (4°C) deep frozen plasma (DFP) will improve strategic stock management, minimize need for resupply, and make preāhospital implementation more feasible. METHODS AND MATERIALS Plasma products type AB of different age and origin (ā30°C Fresh Frozen [(FFP], ā80°C DFP [short (±1 year) and long (±7 year)] stored) were thawed (Day 0), stored at 4°C, and sampled on Days 7 and 14. Additionally, samples of plasma containing blood products (Octaplas LGĀ®, whole blood and platelets) were compared for coagulation factor activity, phospholipid clotting time (PPL), and kaolin TEG during 4°C or 22°C storage. RESULTS Coagulation profiles of FFP, shortā and longāstored ā80°C DFP were not significantly different after thaw. Cold storage did not affect fibrinogen, Protein C, and Antithrombin III activities whereas factor V, VII, VIII, and Protein S decreased in all blood products. After 14 days DFP still meets the guidelines for clinical use, except for Protein S (0.4 IU/mL). With exception of Octaplas LGĀ®, phospholipid activity and TEG coagulation were similar between plasma containing blood components during storage. CONCLUSION AB DFP quality was unaffected by almost 7 years of frozen storage. Quality of thawed 14āday stored AB DFP met, with exception of Protein S, all minimal guidelines which implies that its quality is sufficient for use in the (pre)āhospital (military) environment for treatment of major hemorrhage.
- 21 July 2020
- Published byĀ WileyĀ inĀ Transfusion
- Vol.Ā 60 Ā (8) , 1846-1855
Open AccessProlonged (postāthaw) shelf life of ā80°C frozen AB apheresis plasma
BACKGROUND Early plasma transfusion is important in the treatment of patients with major hemorrhage. Prolonged shelf life of AB type frozen ā80°C and coldāstored (4°C) deep frozen plasma (DFP) will improve strategic stock management, minimize need for resupply, and make preāhospital implementation more feasible. METHODS AND MATERIALS Plasma products type AB of different age and origin (ā30°C Fresh Frozen [(FFP], ā80°C DFP [short (±1 year) and long (±7 year)] stored) were thawed (Day 0), stored at 4°C, and sampled on Days 7 and 14. Additionally, samples of plasma containing blood products (Octaplas LGĀ®, whole blood and platelets) were compared for coagulation factor activity, phospholipid clotting time (PPL), and kaolin TEG during 4°C or 22°C storage. RESULTS Coagulation profiles of FFP, shortā and longāstored ā80°C DFP were not significantly different after thaw. Cold storage did not affect fibrinogen, Protein C, and Antithrombin III activities whereas factor V, VII, VIII, and Protein S decreased in all blood products. After 14 days DFP still meets the guidelines for clinical use, except for Protein S (0.4 IU/mL). With exception of Octaplas LGĀ®, phospholipid activity and TEG coagulation were similar between plasma containing blood components during storage. CONCLUSION AB DFP quality was unaffected by almost 7 years of frozen storage. Quality of thawed 14āday stored AB DFP met, with exception of Protein S, all minimal guidelines which implies that its quality is sufficient for use in the (pre)āhospital (military) environment for treatment of major hemorrhage.